title: Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
abstract: Mitoxantrone-resistant variants of the human HL-60 leukemia cell line are cross-resistant to several natural product and synthetic antineoplastic agents. The resistant cells (HL-60/MX2) retain sensitivity to the Vinca alkaloids vincristine and vinblastine, drugs that are typically associated with the classical multidrug resistance phenotype. Mitoxantrone accumulation and retention are equivalent in the sensitive and resistant cell types, suggesting that mitoxantrone resistance in HL-60/MX2 cells might be associated with an alteration in the type II DNA topoisomerases. We discovered that topoisomerase II catalytic activity in 1.0 M NaCl nuclear extracts from the HL-60/MX2 variant, as measured by the decatenation of Crithidia fasciculata kinetoplast DNA, was reduced 4- to 5-fold compared to that in the parental HL-60 cells. Total cellular topoisomerase II activity in HL-60/MX2 cells was only 50% lower than that in HL-60 cells, however, because the "cytosolic fraction" of the HL-60/MX2 nuclear preparation contained high levels of decatenating activity. Antisera to calf thymus topoisomerase II defined a distinctive immunoreactive pattern of topoisomerase II proteins in crude nuclear extracts from the HL-60/MX2 cells. Both alpha (170 kDa) and beta (180 kDa) forms of topoisomerase II were detected in the HL-60 cell extracts, but only the alpha form was detected in extracts from HL-60/MX2 cells. This finding was associated with the appearance of a new 160-kDa immunoreactive species in nuclear extracts from HL-60/MX2 but not HL-60 cells. Studies were designed to minimize the proteolytic degradation of the topoisomerase II enzymes by extraction of whole cells with hot SDS.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Medical Service, Veterans Affairs Medical Center, Salt Lake City, Utah 84148.
authors.forename: W G
authors.initials: WG
authors.lastname: Harker
authors.forename: D L
authors.initials: DL
authors.lastname: Slade
authors.forename: F H
authors.initials: FH
authors.lastname: Drake
authors.forename: R L
authors.initials: RL
authors.lastname: Parr
mesh_terms: D002384:Catalysis / Q000187:drug effects; D002460:Cell Line; D002467:Cell Nucleus / Q000201:enzymology; D004249:DNA Damage; D004264:DNA Topoisomerases, Type I / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000187:drug effects*; D004351:Drug Resistance / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007038:Hypotonic Solutions; D007527:Isoenzymes / Q000187:drug effects*; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics*; D008942:Mitoxantrone / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D007038:Hypotonic Solutions; D007527:Isoenzymes; D008942:Mitoxantrone; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II